Early Canadian Real-World Experience with Brolucizumab in Anti-Vascular Endothelial Growth Factor-Experienced Patients with Neovascular Age-Related Macular Degeneration: A Retrospective Chart Review

PURPOSE: To assess early real-world outcomes with brolucizumab in Canadian patients with neovascular age-related macular degeneration (nAMD) for which they previously received ≥1 anti-vascular endothelial growth factor (anti-VEGF) agent(s). PATIENTS AND METHODS: This multisite, real-world, retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Giunta, Michel, Gauvin Meunier, Louis-Pierre, Nixon, Donald, Steeves, Jeff, Noble, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440677/
https://www.ncbi.nlm.nih.gov/pubmed/36065355
http://dx.doi.org/10.2147/OPTH.S376199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440677/
https://www.ncbi.nlm.nih.gov/pubmed/36065355
http://dx.doi.org/10.2147/OPTH.S376199

Ejemplares similares